NMS Labs launches its groundbreaking test that will allow medical researchers, health care, occupational and environmental medicine practitioners to accurately measure Bisphenol-A (BPA) in their patients. This is a timely release due to the FDA’s recent reversal of its position on BPA’s potentially harmful effects and the National Toxicology Program’s (NTP) official position. Researchers funded by the American Recovery and Reinvestment Act administered by the National Institute of Environmental Health Sciences (NIEHS)/National Institutes of Health (NIH) continue to investigate toxicity concerns of BPA.

NMS Labs is the only known commercial laboratory to be currently performing a BPA urine test. The company provides this test guided by highly skilled toxicologists who continue to monitor BPA research and the potential benefit of testing in respect to exposure. While this testing does not correlate directly with toxicity, it does offer comparative data to established population statistics for measured BPA in urine.

In addition to BPA, NMS Labs is in the final stages of development for phthalate metabolite testing. Along with BPA and other substances, phthalates have generated concern as potential “endocrine disruptors,” that is, compounds capable of interfering with normal and developing endocrine function.